Clinical Trial Update: Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 study assessing the effect of hepatic impairment on pharmacokinetics, safety, and tolerability of PF-06865571 in subjects with hepatic impairment and he…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Impairment

Drugs mentioned

• PF-06865571

Snippet

Sponsor: Pfizer | Conditions: Hepatic Impairment, Healthy Volunteers | Phase 1 | Status: COMPLETED | Results posted: 2021-04-13